MDxHealth SA has signed a lease agreement for a state-of-the-art laboratory and office facilities in Irvine, Calif, and has filed for CLIA certification of the US site. In addition, MDxHealth has filed for CLIA certification of its Liege facility.
The two-pronged commercialization strategy of the company is built on the development of companion diagnostics with top-tier pharmaceutical companies, and on developing its own proprietary diagnostic, prognostic, and predictive assays for a number of cancer indications to be commercialized through its CLIA laboratories. MDxHealth expects to launch its first assay for prostate cancer in 2012.
In addition, MDxHealth has hired Miriam Reyes, as senior director laboratory operations, and Beth Davis as senior director managed care. Both bring extensive experience in molecular cancer diagnostics to MDxHealth.